SCHEMBL260278

SCHEMBL260278

O=C1Cc2cc(CO)ccc2N1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 4/20 0.56
GAA P10253 2/20 0.54
MAOB P27338 3/20 0.51
SMYD3 Q9H7B4 3/20 0.51
PDE3B Q13370 1/20 0.50
PDE3A Q14432 1/20 0.50
PDK2 Q15119 1/20 0.48
EPHX2 P34913 2/20 0.47
GRIA1 P42261 2/20 0.46
CACNG8 Q8WXS5 2/20 0.46
PGR P06401 1/20 0.46
HTR1A P08908 1/20 0.44
DRD2 P14416 1/20 0.44
ADRA1D P25100 1/20 0.44
HTR2A P28223 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL260866 0.86 AHR (0.53) AHRGAAMAOBSMYD3PDE3B
SCHEMBL2811609 0.86 AHR (0.56) AHRGAAMAOBSMYD3PDE3B
SCHEMBL29746650 0.86 AHR (0.56) AHRGAAMAOBSMYD3PDE3B
SCHEMBL8670836 0.85 AHR (0.59) AHRMAOBSMYD3PDE3BPDE3A
SCHEMBL19376194 0.84 MAOA (0.51) MAOBPDE3BPDE3AHTR1ADRD2
SCHEMBL24570672 0.82 AHR (0.61) AHRGAAMAOBSMYD3PDE3B
SCHEMBL1681854 0.82 AHR (0.56) AHRGAAMAOBSMYD3PDE3B
SCHEMBL22636513 0.82 AHR (0.56) AHRGAAMAOBSMYD3PDE3B
SCHEMBL260951 0.82 AHR (0.56) AHRGAAMAOBSMYD3PDE3B
SCHEMBL9435130 0.82 AHR (0.56) AHRGAAMAOBSMYD3PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1961748-A2 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors AstraZeneca AB (SE) 2008-08-27 EP claimed
CN-1923812-A New compounds ASTRAZENECA AB (SE) 2007-03-07 CN claimed
CN-1642938-A Novel compounds ASTRAZENECA AB (SE) 2005-07-20 CN claimed
US-20050153987-A1 Compounds ASTRAZENECA AB (SE) 2005-07-14 US claimed
US-20240083908-A1 TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS ALIVEXIS, INC. (JP) 2024-03-14 US disclosed
EP-4269415-A1 TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND Modulus Discovery, Inc. (JP) 2023-11-01 EP disclosed
US-20230257396-A1 MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS INC (US) 2023-08-17 US disclosed
US-20230257396-A1 MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS INC (US) 2023-08-17 US disclosed
CN-116583286-A Tetrahydrothienopyrimidine sulfonamide compounds 某久拉斯株式会社 2023-08-11 CN disclosed
WO-2022138812-A1 TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND モジュラス株式会社 2022-06-30 WO disclosed
WO-2022011123-A1 MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS, INC. (US) 2022-01-13 WO disclosed
US-9956302-B2 Compounds and compositions for the treatment of ocular disorders Graybug Vision, Inc. (US) 2018-05-01 US disclosed
CN-1923812-A New compounds ASTRAZENECA AB (SE) 2007-03-07 CN disclosed
EP-1706376-A1 IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2006-10-04 EP disclosed
CN-1642938-A Novel compounds ASTRAZENECA AB (SE) 2005-07-20 CN disclosed
US-20050153987-A1 Compounds ASTRAZENECA AB (SE) 2005-07-14 US disclosed
WO-2005054188-A1 IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2005-06-16 WO disclosed
EP-1492785-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2005-01-05 EP disclosed
WO-2003082853-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2003-10-09 WO disclosed
WO-2001090103-A9 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS SUGEN INC (US) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240083908-A1 TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS TYMS, TYMP, TPMT AHR 3341/4885GAA 3336/4885MAOB 3268/4885
US-20230257396-A1 MACROCYCLES AND THEIR USE VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DLD AHR 574/4885GAA 520/4885MAOB 2033/4885
US-20050153987-A1 Compounds SDHA, CYP11B2, CYP11B1 AHR 2669/4885GAA 43/4885MAOB 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.